Stock Events

Macrogenics 

€14.82
2
+€0+0% Friday 06:01

Statistics

Day High
14.82
Day Low
14.82
52W High
-
52W Low
-
Volume
0
Avg. Volume
-
Mkt Cap
976.57M
P/E Ratio
-107.81
Dividend Yield
-
Dividend
-

Upcoming

Earnings

7MayExpected
Q3 2022
Q4 2022
Q1 2023
Q2 2023
Q3 2023
Q4 2023
Next
-0.75
-0.19
0.36
0.92
Expected EPS
-0.62
Actual EPS
N/A

People Also Follow

This list is based on the watchlists of people on Stock Events who follow M55.F. It's not an investment recommendation.

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.

Analyst Ratings

22.14Average Price Target
The highest estimate is €29.
From 9 ratings within the last 6 months. This is not an investment recommendation.
Buy
78%
Hold
22%
Sell
0%

About

MacroGenics, Inc., a biopharmaceutical company, develops, manufactures, and commercializes antibody-based therapeutics to treat cancer in the United States. Its approved product is MARGENZA (margetuximab-cmkb), a human epidermal growth factor receptor 2 (HER2) receptor antagonist indicated, in combination with chemotherapy, for the treatment of adult patients with metastatic HER2-positive breast cancer who have received two or more prior anti-HER2 regimens. The company's pipeline of immuno-oncology product candidates includes MGC018, an antibody drug conjugate (ADC), which targets solid tumors expressing B7-H3; Enoblituzumab, a monoclonal antibody that targets B7-H3; and MGD024, an investigational bispecific CD123 × CD3 DART molecule to minimize cytokine-release syndrome for patients with hematologic malignancies. In addition, it develops Lorigerlimab, a monoclonal antibody that targets the immune checkpoints PD-1 and cytotoxic T-lymphocyte-associated protein 4; Tebotelimab, an investigational tetravalent DART molecule for PD-1 and lymphocyte-activation gene 3; Retifanlimab, a humanized monoclonal antibody targeting programmed death receptor-1; and IMGC936, an ADC that targets ADAM9, a cell surface protein over-expressed in various solid tumor types. Further, the company develops MGD014 and MGD020, a DART molecule to target the envelope protein of human immunodeficiency virus infected cells and CD3 on T cells; Teplizumab for the treatment of type 1 diabetes; and PRV-3279, a CD32B × CD79B DART molecule for the treatment of autoimmune indications. It has collaborations with Incyte Corporation; Zai Lab Limited; I-Mab Biopharma; and Janssen Biotech, Inc. The company was incorporated in 2000 and is headquartered in Rockville, Maryland.
Show more...
CEO
Dr. Scott Koenig M.D., Ph.D.
Employees
339
Country
US
ISIN
US5560991094
WKN
000A1W6ND

Listings